Category

Biotech

Artificial Intelligence, Robots And Techcrunch Disrupt

By | Artificial Intelligence, Biotech, Current Affairs, Entrepreneurs, Events, Investor and VC News, Knowledge, Robots

  In early December, Techcrunch Disrupt London came to town. The event hosts Startup Battlefield which gathers early stage startups together on one stage to compete for the Disrupt Cup and a cash prize. As expected, the agenda was jam-packed with a wide-range topics from Brexit and walking robot dogs to flying cars and the continued disruption and innovation of Fintech. On the VC front On the venture capital front, Niklas Zennström, Atomico said that early stage Seed and Series A investments in Europe are now on par with the US, both in terms of amount of capital invested and number of companies….

Read More

Ins and Outs of Clinical Trials: Publication Rights

By | Biotech, Knowledge, Life Sciences

Looking back to our last post in the Ins and Outs series on Confidentiality, you’ll see there’s an obvious disconnect and therefore potential conflict in relation to publication rights between a sponsor and the principal investigator (PI)/institution. Onerous restrictions on publication rights could be counterproductive and unlikely to be accepted by the institution and PI. For a start, it could potentially sour the goodwill and alliance established between the institution, PI and sponsor prior to commencing the clinical trial. Further, sponsors understand that for many institutions and PIs, in addition to facilitating the development of new medicines, conducting clinical trials has the allure…

Read More

Cross Border M&A Success

By | Biotech, Client news, Knowledge, Life Sciences, M&A

In Life Science news, Akarna Therapeutics Ltd. was acquired by Allergan plc (NYSE: AGN) for an upfront cash payment of $50 million. JAG Shaw Baker acted on behalf of New Science Ventures LLC, a New York venture capital fund that invests in novel scientific approaches. New Science Ventures was one of the selling shareholders alongside Third Point Ventures and Forbion Capital Partners. Akarna Therapeutics is a UK company with offices in Cambridge, UK and San Diego, California. Akarna Therapeutic’s lead product candidate (AKN-083) is considered an effective and novel treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. An M&A…

Read More

The Top Four Tips You Need to Prep For A Biotech IPO

By | Biotech, Current Affairs, Knowledge, Life Sciences, Partner Insight

Biotech companies have fared well recently in the IPO market in both the US and the UK. New legislation in the US has eased access to public markets and the AIM market in London continues to be attractive for emerging biotech companies. If you’re considering an IPO to raise capital for your biotech company, here are the four top tips you need to prep you on how to prepare for your big launch. 1. Intellectual property is key Wrap up any and all Intellectual Property (IP) issues before kicking off an IPO process. Most advisors and investors are not as…

Read More

A New Blog Series: The Ins And Outs Of Clinical Trials

By | Biotech, Knowledge, Life Sciences

In our new 10 part blog series on clinical trials, Sharmela Thevarajaha, Associate, Intellectual Property and Life Sciences, brings her wealth of private practice and in-house experience with clients such as Sanofi and Takeda, to take a look at some key clauses within a sponsor-initiated clinical trial agreement. In the series she highlights the crucial legal, ethical and business issues to consider when negotiating these key provisions including payments, intellectual property, insurance and publication rights. ______ Clinical research collaboration plays a significant role in developing medicines, advancing medical knowledge and enhancing patient care.   Without clinical trials, pharmaceutical companies (the…

Read More

Elasmogen Spins Out Of The University Of Aberdeen

By | Biotech, Client news, Investor and VC News, investors, Life Sciences

In spin out news, we advised Elasmogen on a variety of corporate and commercial matters in connection with its spin out from the University of Aberdeen. Elasmogen is a biologics drug discovery company that specialises in antibody-like proteins called soloMER. Our legal team advised and negotiated on a variety of corporate, commercial and IP agreements, including, a subscription and shareholders’ agreement, patent licence agreements, material transfer, facilities and management and secondment agreements.

Read More

Morphogen-IX Raises £1.5M From Index Ventures

By | Biotech, Client news, investors, Startups

Cambridge-based Morphogen-IX just raised a £1.5 seed round led by Index Ventures. The company is a spin-out from Cambridge University which is working on a treatment for pulmonary arterial hypertension (PAH) which affects about 6,500 people in the UK alone. PAH is caused by the narrowing of blood vessels that lead from the heart to the lungs. When these arteries narrow, it becomes harder for the heart to pump blood through to the lungs, leading to breathlessness and heart failure. The round also included investment from Cambridge Innovation Capital and Cambridge Enterprise Seed Funds. The company says it’s dedicated to developing a therapy that will…

Read More

Introducing UKISS For The UK Startup Market

By | Biotech, Investor and VC News

When you’re part of an ecosystem as robust as the UK start-up market, sometimes the best way to help a market continue to grow is by doing. This is why we’re proud to have co-drafted UKISS & ASA documents for 500 Startups. The docs are great resources for founder agreements, advisor agreements, IP assignment agreements and term sheets and will be posted to 500 Startups’s KISS Portal. Some of Silicon Valley ecosystem’s success is due to legal framework that’s been created. Framework documents like NVCA, Series Seed, KISS and SAFE have helped to standardize how deals get done. The UK…

Read More

A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. more information

INFORMATION ABOUT OUR USE OF COOKIES Our website uses cookies to distinguish you from other users of our website. This helps us to provide you with a good experience and also allows us to improve our website. By continuing to browse the website, you are agreeing to our use of cookies. A cookie is a small file of letters and numbers that we store on your browser or computer, phone or tablet hard drive if you agree. We use the following cookies: • Strictly necessary cookies. These are cookies that are required for the operation of our website. They include, for example, cookies that enable you to return to a previous page. • Analytical/performance cookies. They allow us to recognise and count the number of visitors and to see how visitors move around our website when they are using it. This helps us to improve the way our website works, for example, by ensuring that users are finding what they are looking for easily. The analytical/performance cookies are provided on our behalf by Google Inc. to aid with reporting of user behaviour, market research and improving website functionality. This user behaviour is analysed in order to improve this website. To see how this applies to Google Analytics, visit http://www.google.co.uk/intl/en/analytics/privacyoverview.html. You can stop tracking by Google Analytics by visiting https://tools.google.com/dlpage/gaoptout?hl=en-GB. COOKIE DURATION The strictly necessary session cookies are a temporary cookie which remains in the cookie file of your browser until you close the browser. The other cookies will remain in the cookie file of your browser after the closing of the browser, and will become active again when you reopen this website. The different cookies have different expiration dates. Following expiry of a cookie, a new version of that cookie will be downloaded when you next visit this website, unless you have withdrawn your consent in the meantime. You can block cookies by activating the setting on your browser that allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or parts of our website. Contact If you have any queries regarding this cookie policy please contact us at info@jagshawbaker.com.

Close